Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Vertex Pharmaceuticals Incorporated

< Previous 1 2 3 4 5 Next >
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Reports Third-Quarter 2021 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Announce Third-Quarter 2021 Financial Results on November 2
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Reports Second-Quarter 2021 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Announce Second-Quarter 2021 Financial Results on July 29
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces National Reimbursement Agreement in France for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO®, SYMKEVI® and Additional Indications of ORKAMBI® and KALYDECO® for Eligible Patients With Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers CRSP VRTX
Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
CORRECTING and REPLACING Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.